GLP-1 mimetics and diabetic ketoacidosis: possible interactions and clinical consequences
The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
Abstract
Diabetic ketoacidosis is a serious diabetes-related consequence that occurs in type 1 diabetes and less commonly in type 2 diabetes and is a major cause of death. It results from the metabolic consequences due to a lack of insulin secretion or impaired insulin activity in diabetes leading to dysregulated pathophysiologic pathways resulting in excessive ketone body formation. While ketone bodies are physiologic molecules, their high levels reduce the physiological pH of the blood and induce ketoacidosis, leading to increasing metabolic dysfunction. Glucagon-like peptide-1 (GLP-1) mimetics are a class of recently developed diabetes therapy that do not lead to hypoglycemic, but some reports have suggested a relationship between GLP-1 mimetics and ketogenesis. To clarify the possible interactions between GLP-1 mimetics and ketogenesis in diabetes, this review was undertaken to collate and interpret the literature.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Global estimates of the prevalence of diabetes for 2010 and 2030
Shaw, J. E., Sicree, R. A., & Zimmet, P. Z. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.10.007 · Cited by 7,216 · cited 1×
“The incidence of diabetes is increasing, mainly caused by the worldwide growth in obesity incidence (Forouhi and Wareham 2010; Shaw et al. 2010).”
DrugBank: a knowledgebase for drugs, drug actions and drug targets
Wishart, D. S., Knox, C., Guo, A. C., Cheng, D., Shrivastava, S., Tzur, D., Gautam, B., & Hassanali, M. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkm958 · Cited by 2,861
2. Classification and Diagnosis of Diabetes:Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Gaglia, J. L., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s002 · Cited by 2,433 · cited 1×
“…diabetes in adults (LADA), maturity-onset diabetes of the young (MODY), and secondary diabetes resulting from conditions such as pancreatitis or certain medications, such as corticosteroids, which together form the fourth category of DM (Roglic 2016; ElSayed et al. 2023; Kaul et al. 2013).”
Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868 · cited 1×
“It is produced by the pro-glucagon gene in the L-cells of the intestine, specifically in the epithelial layer of the ileum and colon (Bryant et al. 1983) and is released on ingestion of a meal (Müller et al. 2019).”
Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics
Puchalska, P., & Crawford, P. A. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2016.12.022 · Cited by 1,610 · cited 1×
“Hepatocytes transform free fatty acids (FFAs) into small, soluble metabolic molecules known as KBs (Ghimire et al. 2023) such as acetone, acetoacetate, and β-hydroxybutyrate (Puchalska and Crawford 2021, 2017).”
Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management
Chaudhury, A., Duvoor, C., Reddy Dendi, V. S., Kraleti, S., Chada, A., Ravilla, R., Marco, A., Shekhawat, N. S., Montales, M. T., Kuriakose, K., et al. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00006 · Cited by 1,500 · cited 1×
“Despite the existence of multiple pharmaceutical interventions for the management of diabetes, the occurrence of DKA remains a concern among individuals with diabetes particularly those treated with insulin (Chaudhury et al. 2017).”
WHO Global report on diabetes: A summary
Roglic, G. (2016) · International Journal of Noncommunicable Diseases · doi:10.4103/2468-8827.184853 · Cited by 998 · cited 3×
“Suboptimal diabetes control gives rise to diabetes-related complications in several organ systems (Roglic 2016; Balaji et al. 2019), with a diminished quality of life, an increased mortality that pose a significant health economic burden (Forouhi and Wareham 2010).”
Ketone bodies as signaling metabolites
Newman, J. C., & Verdin, E. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.09.002 · Cited by 966 · cited 2×
“…and synthesizing specific biomolecules such as sterols, glycer-ophospholipids, and sphingolipids, and also playing a crucial part in the process of histone acetylation and the regulation of gene expression within cells (Puchalska and Crawford 2021; Newman and Verdin 2014; Yaribeygi et al. 2022b).”
Incretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950 · cited 1×
“Incretins are a group of peptides that are released by the gastrointestinal tract after food consumption that include GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) (Nauck and Meier 2018; Yar-ibeygi et al. 2020a).”
Research works printed but not linked: 3
- Balaji R, Duraisamy R, Kumar M (2019) Complications of diabetes mellitus: a review. Drug Invent Today 12(1)
- Caballero B, Trugo L, Finglas P (2003) Encyclopedia of food sciences and nutrition: Volumes 1–10: Elsevier Science BV
- Collins L, Costello R (2020) Glucagon-like peptide-1 receptor agonists. StatPearls. StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK551568/. Accessed 17 Aug 2024
Cited by
Ganamurali, N., & Sabarathinam, S. (2026) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.70001 · Cited by 8
“37 • Surrogate for future poly-agonist platforms : Retatru-tide is not just a single molecule but a proof-of-concept for multi-targeted pharmacotherapy.”
Xu, H., & Zhang, Y. L. (2026) · Medicine · doi:10.1097/md.0000000000046197 · Cited by 3
“[6] In our case, the patient’s preexisting T2DM with poor glycemic control (hemoglobin A1c 11.4”
InfluentialJayasingha, J. M. P. S., Madushan, M. A. H., Jayathilaka, N. S., & Sabarathinam, S. (2026) · Comprehensive physiology · doi:10.1002/cph4.70123
Metadata
- Authors
- Forouzanmehr, B., Hemmati, M. A., Atkin, S. L., Jamialahmadi, T., Yaribeygi, H., & Sahebkar, A.
- Affiliations
- Semnan University of Medical Sciences (IR)
- Royal College of Surgeons in Ireland - Bahrain (BH)
- Mashhad University of Medical Sciences (IR)
- Corresponding author
- Yaribeygi, Habib
- Sahebkar, Amirhossein
- ORCID
- Venue
- Naunyn-Schmiedeberg's Archives of Pharmacology
- Published
- 2024-08-22
- Volume
- 398
- Issue
- 1
- Pages
- 351-362
- ISSN
- 0028-1298 (ISSN-L)
- 1432-1912
- OpenAlex
- W4401793502
- Cited by
- 3
- References
- 113
- Citations by year
- 2026: 3
- FWCI
- 0.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Naunyn-Schmiedeberg s Archives of Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Physiology (medical) › Diet and metabolism studies
- Keywords
- GLP-1 receptor agonists, diabetic ketoacidosis, ketogenesis, ketone bodies, type 1 diabetes, type 2 diabetes, insulin deficiency, drug interactions, metabolic dysfunction
- MeSH terms
- Animals, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Ketone Bodies, Diabetic Ketoacidosis, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.